ALETA-001

Phase 2Small molecule

CCancer Research UK

ALETA-001 is one of 19 small molecule programs targeting B-cell Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

B-Cell MalignanciesRecruiting

B-Cell MalignanciesPhase 2

Recruiting

Competition

Competitive Landscape

21 competitors in B-Cell Malignancies

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

2 2

Brukinsa

BBeOne Medicines

Phase 3

5 3

Fludara

Sanofi

Phase 2

8 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

8 5

Libtayo

Regeneron

Phase 1

1 6

Parsaclisib

Incyte

Phase 2

2 7

Treanda

AAzurity Pharmaceuticals

Phase 1

1 8

Fabhalta

BBellicum Pharmaceuticals

Phase 1

1 9

Odronextamab

Regeneron

Phase 1

2 10

IL-2

FFate Therapeutics

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1/2Recruiting

B-Cell Malignancies

NCT06045910

Clinical

Trials by Indication[1]

B-cell Malignancies1 trial

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Recruiting·CCancer Research UK·Phase 1/2·NCT06045910·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALETA-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALETA-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALETA-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cancer Research UK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCancer Research UK

ALETA-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

B-cell Malignancies1 trial

References

Drug Info

Quick Facts

Related News